CCI
XLRN

Columbus Circle Investors’s Acceleron Pharma XLRN Stock Holding History

Columbus Circle Investors’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-11,828
Closed -$441K – 293
2017
Q3 		$441K Buy
+11,828
New +$411K 0.01% 278

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Columbus Circle Investors's XLRN Position: Q4 2017 in Review

Columbus Circle Investors sold out of Acceleron Pharma (XLRN) in Q4 2017, closing a stake of 11,828 shares — an estimated $441K sold.

Columbus Circle Investors first reported a position in XLRN in Q3 2017 and held it in 1 quarter. The position peaked at $441K in Q3 2017. 137 funds tracked by Wall St. Rank hold XLRN as of Q4 2017.

  • Columbus Circle Investors reported no remaining Acceleron Pharma position as of Q4 2017 after selling out during the quarter.
  • Columbus Circle Investors sold 11,828 Acceleron Pharma shares in Q4 2017, an estimated $441K.
  • Columbus Circle Investors first reported a position in Acceleron Pharma in Q3 2017 and held it in 1 quarter.
  • Columbus Circle Investors's Acceleron Pharma position peaked at $441K in Q3 2017.
  • 137 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2017.

Based on Columbus Circle Investors's 13F filing for Q4 2017, filed 2 Feb 2018.